Search Results

Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island.

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.

The acquisition of the contract development and manufacturing organization will allow Agilent Technologies to provide a one-stop source for gene-editing services for its customers.

BIOVECTRA announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada.

BIOVECTRA Inc., a forward-thinking global contract development and manufacturing organization, launched a new logo and brand to align with the growing company’s full suite of expertise and core values.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing and BIOVECTRA, a CDMO specializing in clinical-to-commercial scale production of high-quality regulated Biologics, Active Pharmaceutical Ingredients, and intermediates, today announced ABEC will design, manufacture, and install CSR single-use microbial fermentation solutions at BIOVECTRA’s manufacturing facility in Windsor, Nova Scotia, Canada.

BIOVECTRA is proud to be selected as one of Canada’s Top 100 Employers for 2022 and considered amongst some of the country’s leading workplaces.